A Phase II Study of Carboplatin and Prolonged Administration of Oral Etoposide in Patients with Small-Cell Lung Cancer

Prolonged oral administration of etoposide may have a theoretical advantage over intravenous infusion, and carboplatin has a more favorable toxicity profile than cisplatin. A combination of carboplatin 300 mg/m2 and oral etoposide 40 mg/m2/day for 21 days was assessed in 74 (42 limited, 32 extensive...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 1997, Vol.36 (7), p.765-769
Main Authors: Minami, Hironobu, Saka, Hideo, Sakai, Shuzo, Yamamoto, Masashi, Shimokata, Kaoru
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin - administration & dosage
Carcinoma, Small Cell - drug therapy
Etoposide - administration & dosage
Female
Humans
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Neutropenia - chemically induced
Pneumology
Survival Rate
Thrombocytopenia - chemically induced
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prolonged oral administration of etoposide may have a theoretical advantage over intravenous infusion, and carboplatin has a more favorable toxicity profile than cisplatin. A combination of carboplatin 300 mg/m2 and oral etoposide 40 mg/m2/day for 21 days was assessed in 74 (42 limited, 32 extensive disease) previously untreated patients with small-cell lung cancer. Response rate was 69% (CR 19%, PR 50%) for limited disease and 72% (CR 9%. PR 63%) for extensive disease. Median response duration and overall survival was 6.6 and 10.1 months for limited disease, and 5.3 and 9.1 months for extensive disease, respectively. One-year and two-year survival was 36 and 10% for limited disease and 31 and 2% for extensive disease, respectively. The major toxicity was hematological with grade 4 or greater neutropenia in 36% and grade 4 thrombocytopenia in 16% and one patient died of neutropenic fever. Non-hematologic toxicities were mild and grade 3 emesis was observed in 5% of patients. Carboplatin combined with 21-day oral etoposide showed only modest activity against small-cell lung cancer with high toxicity and did not merit further evaluation.
ISSN:0284-186X
1651-226X
DOI:10.3109/02841869709001352